Published in Clin Exp Metastasis on June 18, 2011
The multifaceted actions of PTHrP in skeletal metastasis. Future Oncol (2012) 0.89
Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PLoS One (2012) 0.87
The incidence of EGFR-activating mutations in bone metastases of lung adenocarcinoma. Pathol Oncol Res (2013) 0.82
Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway. Sci Transl Med (2014) 0.82
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol (2015) 0.80
Emerging lung cancer therapeutic targets based on the pathogenesis of bone metastases. Int J Cell Biol (2014) 0.78
At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone. Odontology (2012) 0.78
EGFR Regulates the Development and Microarchitecture of Intratumoral Angiogenic Vasculature Capable of Sustaining Cancer Cell Intravasation. Neoplasia (2015) 0.78
Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression. Clin Exp Metastasis (2011) 0.77
Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC. Mol Cancer Res (2015) 0.76
Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways. BMB Rep (2017) 0.75
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer (2002) 17.49
Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer (2002) 12.45
Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 6.57
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol (2005) 5.07
Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov (2003) 2.32
Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res (2008) 2.30
Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg (1996) 2.21
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer (2006) 2.04
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol (2008) 1.98
Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun (2005) 1.69
HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood (2005) 1.62
Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res (2007) 1.55
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat (2005) 1.53
Mechanisms of cancer metastasis to the bone. Cell Res (2005) 1.49
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs (2004) 1.47
Parathyroid hormone related protein and hypercalcaemia in breast cancer. BMJ (1991) 1.41
Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res (2001) 1.36
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. J Thorac Oncol (2008) 1.34
Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J Biol Chem (2004) 1.24
Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res (2003) 1.24
Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch (2005) 1.20
Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res (2006) 1.18
Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC. J Biomed Biotechnol (2010) 1.16
Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res (2003) 1.13
Induction of experimental bone metastasis in mice by transfection of integrin alpha 4 beta 1 into tumor cells. Am J Pathol (1996) 1.12
Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer (2005) 1.12
Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling. J Cell Physiol (2008) 1.11
RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol (2002) 1.10
Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol (2003) 1.04
Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev (2009) 1.00
Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr Relat Cancer (2006) 1.00
The EGFR network in bone biology and pathology. Trends Endocrinol Metab (2009) 0.98
Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice. Br J Cancer (2007) 0.92
Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer (1998) 0.90
Defective bone remodelling in osteoprotegerin-deficient mice. J Electron Microsc (Tokyo) (2003) 0.90
Bone-breaking cancer treatment. Nat Med (2007) 0.89
1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. J Bone Miner Metab (2009) 0.87
CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. Nat Clin Pract Oncol (2007) 0.84
Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. Lung Cancer (2008) 0.83
Prolonged response to gefitinib in bone metastasis. Med Oncol (2008) 0.79
[Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis]. Clin Calcium (2008) 0.79
Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy. Cancer Chemother Pharmacol (2009) 1.52
Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol (2006) 1.51
Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine (2002) 1.34
Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res (2011) 1.33
Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs (2010) 1.12
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol (2005) 1.09
Combination of fixation using PLP fixative and embedding in paraffin by the AMeX method is useful for histochemical studies in assessment of immunotoxicity. J Toxicol Sci (2002) 1.09
Analysis of the function of a hyperthermophilic endoglucanase from Pyrococcus horikoshii that hydrolyzes crystalline cellulose. Extremophiles (2004) 1.09
Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. Int J Hematol (2012) 1.05
Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst (2003) 1.02
Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci (2012) 1.01
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol Pharm Bull (2008) 0.99
A role of cytokines in OK-432 injection therapy for cystic lymphangioma: an approach to the mechanism. J Pediatr Surg (2003) 0.96
Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer Res (2004) 0.96
Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. J Immunother (2005) 0.95
Evidence of immunostimulating lipoprotein existing in the natural lipoteichoic acid fraction. Infect Immun (2007) 0.95
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS. Oncol Rep (2010) 0.93
In vivo confocal microscopy of hereditary sensory and autonomic neuropathy. Curr Eye Res (2008) 0.90
Clinical characteristics of human immunodeficiency virus-associated Hodgkin lymphoma patients in Japan. Int J Hematol (2012) 0.88
Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment. Cancer Res (2010) 0.87
Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization. Gastric Cancer (2014) 0.87
Possible expansion of "Window of Implantation" in pseudopregnant mice: time of implantation of embryos at different stages of development transferred into the same recipient. Biol Reprod (2003) 0.86
Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4. J Immunother (2004) 0.86
Nicorandil improves glomerular injury in rats with mesangioproliferative glomerulonephritis via inhibition of proproliferative and profibrotic growth factors. J Pharmacol Sci (2009) 0.85
Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent. J Immunother (2006) 0.85
Sensitivity and specificity with the glaucoma probability score in Heidelberg Retina Tomograph II in Japanese eyes. J Glaucoma (2009) 0.84
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts. Oncol Rep (2011) 0.84
Effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin-induced lung injury of varying severity. Toxicol Pathol (2003) 0.83
An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma. J Pathol (2014) 0.83
Motif-based search for a novel fructosyl peptide oxidase from genome databases. Biotechnol Bioeng (2010) 0.82
Scanning laser polarimetry with enhanced corneal compensation in patients with open-angle glaucoma. J Glaucoma (2008) 0.82
Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka. Int J Hematol (2010) 0.82
Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy. Int J Oncol (2004) 0.81
Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models. Oncol Rep (2009) 0.81
Increased mobilization of c-kit+ Sca-1+ Lin- (KSL) cells and colony-forming units in spleen (CFU-S) following de novo formation of a stem cell niche depends on dynamic, but not stable, membranous ossification. J Cell Physiol (2006) 0.81
Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts. Oncol Rep (2007) 0.81
Biomarkers for antitumor activity of bevacizumab in gastric cancer models. BMC Cancer (2012) 0.80
A method to measure visual field sensitivity at the edges of glaucomatous scotomata. Invest Ophthalmol Vis Sci (2014) 0.80
Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome. Am J Nephrol (2012) 0.79
Expression, purification, crystallization and preliminary crystallographic analysis of a deblocking aminopeptidase from Pyrococcus horikoshii. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 0.78
Clinical manifestation and prognostic factors of 32 Japanese patients with autoimmune disease-associated diffuse large B-cell lymphoma. Leuk Lymphoma (2014) 0.78
Activation of AXL and antitumor effects of a monoclonal antibody to AXL in lung adenocarcinoma. Anticancer Res (2014) 0.78
Effect of erythropoietin on human tumor growth in xenograft models. Mol Med Rep (2011) 0.78
Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. Cancer Chemother Pharmacol (2006) 0.78
Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice. Int J Hematol (2014) 0.78
Stabilization of fungi-derived recombinant FAD-dependent glucose dehydrogenase by introducing a disulfide bond. Biotechnol Lett (2015) 0.77
Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression. Clin Exp Metastasis (2011) 0.77
Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers. Oncol Lett (2010) 0.77
[Microarray analysis of tumor xenograft model]. Gan To Kagaku Ryoho (2010) 0.77
Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes. Oncol Rep (2012) 0.77
Left ventricular hypertrophy is associated with inflammation in sodium loaded subtotal nephrectomized rats. Biomed Res (2011) 0.77
High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancers. Oncol Lett (2010) 0.77
Involvement of nitric oxide in anti-tumor effects of OK-432, a streptococcal anti-tumor immunotherapeutic agent. Int Immunopharmacol (2005) 0.77
Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells. Anticancer Res (2003) 0.77
Melting curve analysis for mutations of EGFR and KRAS. Anticancer Res (2014) 0.77
Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts. Oncol Rep (2011) 0.76
[Therapy-related acute myeloid leukemia following double autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma]. Rinsho Ketsueki (2002) 0.76
Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure. Nephrol Dial Transplant (2002) 0.75
Inversion of chromosome 7q22 and q36 as a sole abnormality presenting in myelodysplastic syndrome: a case report. J Med Case Rep (2014) 0.75
Enhancement of antitumor activity of OK-432 (picibanil) by Triton X-114 phase partitioning. Int Immunopharmacol (2007) 0.75
Anterior gradient 2 is correlated with EGFR mutation in lung adenocarcinoma tissues. Int J Biol Markers (2015) 0.75
Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer. Chemotherapy (2005) 0.75
[Effects of intravenous and oral OCT on secondary hyperparathyroidism in dogs with chronic renal failure]. Clin Calcium (2002) 0.75
[Evaluation of quality of life characteristics and grade of legal visual impairment]. Nippon Ganka Gakkai Zasshi (2007) 0.75
Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-gamma-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction. Int Immunopharmacol (2003) 0.75
Phase-locked laser system for a metastable states qubit in 40 Ca+. Opt Lett (2007) 0.75
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma. Intern Med (2012) 0.75